10th Dermatology Drug Development Summit The Colonnade Hotel, Boston

The dermatology market is entering a pivotal new era. As competition intensifies across Atopic Dermatitis and Psoriasis, developers are under growing pressure to demonstrate meaningful differentiation, accelerate development timelines and identify the next generation of high-value opportunities beyond today’s established targets and therapies.

The 10th Dermatology Drug Development Summit is the industry’s premier forum dedicated to advancing the discovery, development, and commercialization of innovative therapies for inflammatory skin disease.

Bringing together 90+ leaders from the likes of AbbVie, Galderma, Merck, SUN Pharma, Eli Lilly, UNION Therapeutics and more, spanning discovery, translational medicine, preclinical development, clinical strategy, medical affairs, and commercial functions, the meeting provides a unique opportunity to benchmark emerging science, evaluate novel targets, and share practical lessons from across the dermatology pipeline.

This year’s expanded program explores the future of dermatology innovation across Atopic Dermatitis, Psoriasis, Hidradenitis Suppurativa, Vitiligo, Alopecia Areata, Acne, Epidermolysis Bullosa, Prurigo Nodularis, and more.

With dedicated Discovery and Preclinical and Clinical and Commercial tracks, attendees will gain actionable insights into AI-enabled target discovery, translational de-risking, biomarker development, next-generation modalities, dosing optimization, clinical differentiation, and commercialization strategy.

Join the companies shaping the future of dermatology to discover where the next breakthrough therapies and the next major market opportunities will emerge.